Stroke Management Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2021-2030

The global stroke management market was valued at $31,702.20 million in 2020, and is projected to reach $67,771.95 million by 2030, registering a CAGR of 7.8% from 2021 to 2030.

Stroke is caused by lack of blood flow to the brain which can be caused either due to the blockage of the blood supply or a blood vessel within the brain. Such blood insufficiency causes the brain tissue to die, owing to lack of oxygen for the functioning of the brain, eventually resulting into stroke. Stroke is a medical emergency that requires urgent diagnosis and treatment to minimize brain damage. According to the Centers for Disease Control and Prevention, in 2018, stroke was responsible for one out of every six fatalities caused by cardiovascular disease. Stroke is a leading cause of serious long-term disability. Ischemic stroke, hemorrhagic stroke, and transient ischemic stroke are the three main types of strokes. The main symptoms of stroke are difficulty in speaking, understanding, and walking; headache; numbness or inability to move parts of face, arm, or leg; gradual loss of vision; and others.

Increase in healthcare awareness, rise in incidence of diabetes, surge in number of tobacco users, and growth in geriatric population drive the growth of the market. Moreover, technological advancements for the diagnosis and treatment of stroke also contribute toward the growth of the market. However, high cost of diagnosis and treatment and lack of reimbursement policies are the major barriers for the growth of the market. Ongoing R&D activities in the field of stroke management are expected to offer lucrative opportunities for market expansion during the forecast period.

The stroke management market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into diagnostics and therapeutics. The diagnostics segment is classified into computed tomography scan (CT scan), magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others. The therapeutics segment is classified into tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive. By application, it is segmented into ischemic stroke and hemorrhagic stroke. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans
A comprehensive analysis of the factors that drive and restrain the growth of the stroke management market is provided
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves
Key market players and their strategies have been analyzed to understand the competitive outlook of the market

KEY MARKET SEGMENTS

By Type

Diagnostics
Computed Tomography Scan (CT scan)
Magnetic Resonance Imaging (MRI)
Carotid Ultrasound
Cerebral Angiography
Electrocardiography
Echocardiography
Others
Therapeutics
Tissue Plasminogen Activator
Anticoagulant
Antiplatelet
Antihypertensive

By Application

Ischemic Stroke
Hemorrhagic Stroke

By Region

North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia Pacific
Japan
China
Australia
India
South Korea
Rest of Asia Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

KEY MARKET PLAYERS

Abbott Laboratories
B Braun Melsungen AG
Boston Scientific Corporation
Bristol-Myers Squibb Company
Cardinal Health Inc
General Electric Company
GlaxoSmithKline Plc
Medtronic Plc
Merck & Co, Inc
Siemens AG

Frequently Asked Questions about the Global Stroke Management Market

What is the estimated value of the Global Stroke Management Market?

The Global Stroke Management Market was estimated to be valued at $31702.2 million in 2020.

What is the growth rate of the Global Stroke Management Market?

The growth rate of the Global Stroke Management Market is 7.9%, with an estimated value of $67772.0 million by 2030.

What is the forecasted size of the Global Stroke Management Market?

The Global Stroke Management Market is estimated to be worth $67772.0 million by 2030.

Who are the key companies in the Global Stroke Management Market?

Key companies in the Global Stroke Management Market include Abbott Laboratories, B Braun Melsungen AG, Boston Scientific Corporation, Bristol, Myers Squibb Company, Cardinal Health Inc., General Electric Company, GlaxoSmithKline Plc and Merck & Co., Inc..

Chapter 1: Introduction

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models

Chapter 2: Executive Summary

2.1. Cxo Perspective

Chapter 3: Market Landscape

3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power Among Buyers
3.4. Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. Covid-19 Impact Analysis
3.7. Market Volume and Forecast

Chapter 4: Stroke Management Market, by Type

4.1. Market Overview
4.1.1Market Size and Forecast, by Type
4.2. Diagnostics
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Share Analysis, by Country
4.2.4. Computed Tomography Scan
4.2.4.1. Market Size and Forecast
4.2.4.2.2. Market Volume and Forecast
4.2.5. Magnetic Resonance Imaging
4.2.5.1. Market Size and Forecast
4.2.5.2.2. Market Volume and Forecast
4.2.6. Carotid Ultrasound
4.2.6.1. Market Size and Forecast
4.2.6.2.2. Market Volume and Forecast
4.2.7. Cerebral Angiography
4.2.7.1. Market Size and Forecast
4.2.7.2.2. Market Volume and Forecast
4.2.8. Electrocardiography
4.2.8.1. Market Size and Forecast
4.2.8.2.2. Market Volume and Forecast
4.2.9. Echocardiography
4.2.9.1. Market Size and Forecast
4.2.9.2.2. Market Volume and Forecast
4.2.10. Others
4.2.10.1. Market Size and Forecast
4.2.10.2.2. Market Volume and Forecast
4.3. Therapeutics
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Share Analysis, by Country
4.3.4. Tissue Plasminogen Activator
4.3.4.1. Market Size and Forecast
4.3.4.2.2. Market Volume and Forecast
4.3.5. Anticoagulant
4.3.5.1. Market Size and Forecast
4.3.5.2.2. Market Volume and Forecast
4.3.6. Antiplatelet
4.3.6.1. Market Size and Forecast
4.3.6.2.2. Market Volume and Forecast
4.3.7. Antihypertensive
4.3.7.1. Market Size and Forecast
4.3.7.2.2. Market Volume and Forecast

Chapter 5: Stroke Management Market, by Application

5.1. Market Overview
5.1.1Market Size and Forecast, by Application
5.2. Ischemic Stroke
5.2.1. Market Size and Forecast, by Region
5.2.2. Market Share Analysis, by Country
5.3. Hemorrhagic Stroke
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Share Analysis, by Country

Chapter 6: Stroke Management Market, by Region

6.1. Market Overview
6.1.1Market Size and Forecast, by Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, by Type
6.2.3. Market Size and Forecast, by Application
6.2.4. Market Size and Forecast, by Country
6.2.5. United States Stroke Management Market
6.2.5.1. Market Size and Forecast, by Type
6.2.5.2. Market Size and Forecast, by Application
6.2.6. Canada Stroke Management Market
6.2.6.1. Market Size and Forecast, by Type
6.2.6.2. Market Size and Forecast, by Application
6.2.7. Mexico Stroke Management Market
6.2.7.1. Market Size and Forecast, by Type
6.2.7.2. Market Size and Forecast, by Application
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, by Type
6.3.3. Market Size and Forecast, by Application
6.3.4. Market Size and Forecast, by Country
6.3.5. France Stroke Management Market
6.3.5.1. Market Size and Forecast, by Type
6.3.5.2. Market Size and Forecast, by Application
6.3.6. Germany Stroke Management Market
6.3.6.1. Market Size and Forecast, by Type
6.3.6.2. Market Size and Forecast, by Application
6.3.7. Italy Stroke Management Market
6.3.7.1. Market Size and Forecast, by Type
6.3.7.2. Market Size and Forecast, by Application
6.3.8. Spain Stroke Management Market
6.3.8.1. Market Size and Forecast, by Type
6.3.8.2. Market Size and Forecast, by Application
6.3.9. U. K Stroke Management Market
6.3.9.1. Market Size and Forecast, by Type
6.3.9.2. Market Size and Forecast, by Application
6.3.10. Russia Stroke Management Market
6.3.10.1. Market Size and Forecast, by Type
6.3.10.2. Market Size and Forecast, by Application
6.3.11. Rest of Europe Stroke Management Market
6.3.11.1. Market Size and Forecast, by Type
6.3.11.2. Market Size and Forecast, by Application
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, by Type
6.4.3. Market Size and Forecast, by Application
6.4.4. Market Size and Forecast, by Country
6.4.5. China Stroke Management Market
6.4.5.1. Market Size and Forecast, by Type
6.4.5.2. Market Size and Forecast, by Application
6.4.6. Japan Stroke Management Market
6.4.6.1. Market Size and Forecast, by Type
6.4.6.2. Market Size and Forecast, by Application
6.4.7. India Stroke Management Market
6.4.7.1. Market Size and Forecast, by Type
6.4.7.2. Market Size and Forecast, by Application
6.4.8. South Korea Stroke Management Market
6.4.8.1. Market Size and Forecast, by Type
6.4.8.2. Market Size and Forecast, by Application
6.4.9. Australia Stroke Management Market
6.4.9.1. Market Size and Forecast, by Type
6.4.9.2. Market Size and Forecast, by Application
6.4.10. Thailand Stroke Management Market
6.4.10.1. Market Size and Forecast, by Type
6.4.10.2. Market Size and Forecast, by Application
6.4.11. Malaysia Stroke Management Market
6.4.11.1. Market Size and Forecast, by Type
6.4.11.2. Market Size and Forecast, by Application
6.4.12. Indonesia Stroke Management Market
6.4.12.1. Market Size and Forecast, by Type
6.4.12.2. Market Size and Forecast, by Application
6.4.13. Rest of Asia-Pacific Stroke Management Market
6.4.13.1. Market Size and Forecast, by Type
6.4.13.2. Market Size and Forecast, by Application
6.5. Lamea
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, by Type
6.5.3. Market Size and Forecast, by Application
6.5.4. Market Size and Forecast, by Country
6.5.5. Brazil Stroke Management Market
6.5.5.1. Market Size and Forecast, by Type
6.5.5.2. Market Size and Forecast, by Application
6.5.6. South Africa, Stroke Management Market
6.5.6.1. Market Size and Forecast, by Type
6.5.6.2. Market Size and Forecast, by Application
6.5.7. Saudi Arabia Stroke Management Market
6.5.7.1. Market Size and Forecast, by Type
6.5.7.2. Market Size and Forecast, by Application
6.5.8. Uae Stroke Management Market
6.5.8.1. Market Size and Forecast, by Type
6.5.8.2. Market Size and Forecast, by Application
6.5.9. Argentina Stroke Management Market
6.5.9.1. Market Size and Forecast, by Type
6.5.9.2. Market Size and Forecast, by Application
6.5.10. Rest of LAMEA Stroke Management Market
6.5.10.1. Market Size and Forecast, by Type
6.5.10.2. Market Size and Forecast, by Application

Chapter 7: Company Profiles

7.1. Abbott Laboratories
7.1.1. Company Overview
7.1.2. Key Executives
7.1.3. Company Snapshot
7.1.4. Operating Business Segments
7.1.5. Product Portfolio
7.1.6. Business Performance
7.1.7. Key Strategic Moves and Developments
7.2. B Braun Melsungen AG
7.2.1. Company Overview
7.2.2. Key Executives
7.2.3. Company Snapshot
7.2.4. Operating Business Segments
7.2.5. Product Portfolio
7.2.6. Business Performance
7.2.7. Key Strategic Moves and Developments
7.3. Boston Scientific Corporation
7.3.1. Company Overview
7.3.2. Key Executives
7.3.3. Company Snapshot
7.3.4. Operating Business Segments
7.3.5. Product Portfolio
7.3.6. Business Performance
7.3.7. Key Strategic Moves and Developments
7.4. Bristol Myers Squibb Co.
7.4.1. Company Overview
7.4.2. Key Executives
7.4.3. Company Snapshot
7.4.4. Operating Business Segments
7.4.5. Product Portfolio
7.4.6. Business Performance
7.4.7. Key Strategic Moves and Developments
7.5. Cardinal Health Inc.
7.5.1. Company Overview
7.5.2. Key Executives
7.5.3. Company Snapshot
7.5.4. Operating Business Segments
7.5.5. Product Portfolio
7.5.6. Business Performance
7.5.7. Key Strategic Moves and Developments
7.6. General Electric Company
7.6.1. Company Overview
7.6.2. Key Executives
7.6.3. Company Snapshot
7.6.4. Operating Business Segments
7.6.5. Product Portfolio
7.6.6. Business Performance
7.6.7. Key Strategic Moves and Developments
7.7. GlaxoSmithKline plc
7.7.1. Company Overview
7.7.2. Key Executives
7.7.3. Company Snapshot
7.7.4. Operating Business Segments
7.7.5. Product Portfolio
7.7.6. Business Performance
7.7.7. Key Strategic Moves and Developments
7.8. Medtronic plc
7.8.1. Company Overview
7.8.2. Key Executives
7.8.3. Company Snapshot
7.8.4. Operating Business Segments
7.8.5. Product Portfolio
7.8.6. Business Performance
7.8.7. Key Strategic Moves and Developments
7.9. Merck and Co. Inc.
7.9.1. Company Overview
7.9.2. Key Executives
7.9.3. Company Snapshot
7.9.4. Operating Business Segments
7.9.5. Product Portfolio
7.9.6. Business Performance
7.9.7. Key Strategic Moves and Developments
7.10. Siemens AG
7.10.1. Company Overview
7.10.2. Key Executives
7.10.3. Company Snapshot
7.10.4. Operating Business Segments
7.10.5. Product Portfolio
7.10.6. Business Performance
7.10.7. Key Strategic Moves and Developments

List of Tables

Table 1. Global Stroke Management Market, by Type, 2020-2030 ($Million)
Table 2. Global Stroke Management Market for Diagnostics, by Region, 2020-2030 ($Million)
Table 3. Global Stroke Management Market for Therapeutics, by Region, 2020-2030 ($Million)
Table 4. Global Stroke Management Market, by Application, 2020-2030 ($Million)
Table 5. Global Stroke Management Market for Ischemic Stroke, by Region, 2020-2030 ($Million)
Table 6. Global Stroke Management Market for Hemorrhagic Stroke, by Region, 2020-2030 ($Million)
Table 7. Global Stroke Management Market, by Region, 2020-2030 ($Million)
Table 8. North America Stroke Management, by Type, 2020-2030 ($Million)
Table 9. North America Stroke Management, by Application, 2020-2030 ($Million)
Table 10. United States Stroke Management, by Type, 2020-2030 ($Million)
Table 11. United States Stroke Management, by Application, 2020-2030 ($Million)
Table 12. Canada Stroke Management, by Type, 2020-2030 ($Million)
Table 13. Canada Stroke Management, by Application, 2020-2030 ($Million)
Table 14. Mexico Stroke Management, by Type, 2020-2030 ($Million)
Table 15. Mexico Stroke Management, by Application, 2020-2030 ($Million)
Table 16. Europe Stroke Management, by Type, 2020-2030 ($Million)
Table 17. Europe Stroke Management, by Application, 2020-2030 ($Million)
Table 18. France Stroke Management, by Type, 2020-2030 ($Million)
Table 19. France Stroke Management, by Application, 2020-2030 ($Million)
Table 20. Germany Stroke Management, by Type, 2020-2030 ($Million)
Table 21. Germany Stroke Management, by Application, 2020-2030 ($Million)
Table 22. Italy Stroke Management, by Type, 2020-2030 ($Million)
Table 23. Italy Stroke Management, by Application, 2020-2030 ($Million)
Table 24. Spain Stroke Management, by Type, 2020-2030 ($Million)
Table 25. Spain Stroke Management, by Application, 2020-2030 ($Million)
Table 26. United Kingdom Stroke Management, by Type, 2020-2030 ($Million)
Table 27. United Kingdom Stroke Management, by Application, 2020-2030 ($Million)
Table 28. Russia Stroke Management, by Type, 2020-2030 ($Million)
Table 29. Russia Stroke Management, by Application, 2020-2030 ($Million)
Table 30. Rest of Europe Stroke Management, by Type, 2020-2030 ($Million)
Table 31. Rest of Europe Stroke Management, by Application, 2020-2030 ($Million)
Table 32. Asia-Pacific Stroke Management, by Type, 2020-2030 ($Million)
Table 33. Asia-Pacific Stroke Management, by Application, 2020-2030 ($Million)
Table 34. China Stroke Management, by Type, 2020-2030 ($Million)
Table 35. China Stroke Management, by Application, 2020-2030 ($Million)
Table 36. Japan Stroke Management, by Type, 2020-2030 ($Million)
Table 37. Japan Stroke Management, by Application, 2020-2030 ($Million)
Table 38. India Stroke Management, by Type, 2020-2030 ($Million)
Table 39. India Stroke Management, by Application, 2020-2030 ($Million)
Table 40. South Korea Stroke Management, by Type, 2020-2030 ($Million)
Table 41. South Korea Stroke Management, by Application, 2020-2030 ($Million)
Table 42. Australia Stroke Management, by Type, 2020-2030 ($Million)
Table 43. Australia Stroke Management, by Application, 2020-2030 ($Million)
Table 44. Thailand Stroke Management, by Type, 2020-2030 ($Million)
Table 45. Thailand Stroke Management, by Application, 2020-2030 ($Million)
Table 46. Malaysia Stroke Management, by Type, 2020-2030 ($Million)
Table 47. Malaysia Stroke Management, by Application, 2020-2030 ($Million)
Table 48. Indonesia Stroke Management, by Type, 2020-2030 ($Million)
Table 49. Indonesia Stroke Management, by Application, 2020-2030 ($Million)
Table 50. Rest of Asia-Pacific Stroke Management, by Type, 2020-2030 ($Million)
Table 51. Rest of Asia-Pacific Stroke Management, by Application, 2020-2030 ($Million)
Table 52. LAMEA Stroke Management, by Type, 2020-2030 ($Million)
Table 53. LAMEA Stroke Management, by Application, 2020-2030 ($Million)
Table 54. Brazil Stroke Management, by Type, 2020-2030 ($Million)
Table 55. Brazil Stroke Management, by Application, 2020-2030 ($Million)
Table 56. South Africa, Stroke Management, by Type, 2020-2030 ($Million)
Table 57. South Africa, Stroke Management, by Application, 2020-2030 ($Million)
Table 58. Saudi Arabia Stroke Management, by Type, 2020-2030 ($Million)
Table 59. Saudi Arabia Stroke Management, by Application, 2020-2030 ($Million)
Table 60. Uae Stroke Management, by Type, 2020-2030 ($Million)
Table 61. Uae Stroke Management, by Application, 2020-2030 ($Million)
Table 62. Argentina Stroke Management, by Type, 2020-2030 ($Million)
Table 63. Argentina Stroke Management, by Application, 2020-2030 ($Million)
Table 64. Rest of LAMEA Stroke Management, by Type, 2020-2030 ($Million)
Table 65. Rest of LAMEA Stroke Management, by Application, 2020-2030 ($Million)
Table 66. Abbott Laboratories: Key Executives
Table 67. Abbott Laboratories: Company Snapshot
Table 68. Abbott Laboratories: Operating Segments
Table 69. Abbott Laboratories: Product Portfolio
Table 70. Abbott Laboratories: Key Strategic Moves and Developments
Table 71. B Braun Melsungen Ag: Key Executives
Table 72. B Braun Melsungen Ag: Company Snapshot
Table 73. B Braun Melsungen Ag: Operating Segments
Table 74. B Braun Melsungen Ag: Product Portfolio
Table 75. B Braun Melsungen Ag: Key Strategic Moves and Developments
Table 76. Boston Scientific Corporation: Key Executives
Table 77. Boston Scientific Corporation: Company Snapshot
Table 78. Boston Scientific Corporation: Operating Segments
Table 79. Boston Scientific Corporation: Product Portfolio
Table 80. Boston Scientific Corporation: Key Strategic Moves and Developments
Table 81. Bristol Myers Squibb Co. : Key Executives
Table 82. Bristol Myers Squibb Co. : Company Snapshot
Table 83. Bristol Myers Squibb Co. : Operating Segments
Table 84. Bristol Myers Squibb Co. : Product Portfolio
Table 85. Bristol Myers Squibb Co. : Key Strategic Moves and Developments
Table 86. Cardinal Health Inc. : Key Executives
Table 87. Cardinal Health Inc. : Company Snapshot
Table 88. Cardinal Health Inc. : Operating Segments
Table 89. Cardinal Health Inc. : Product Portfolio
Table 90. Cardinal Health Inc. : Key Strategic Moves and Developments
Table 91. General Electric Company: Key Executives
Table 92. General Electric Company: Company Snapshot
Table 93. General Electric Company: Operating Segments
Table 94. General Electric Company: Product Portfolio
Table 95. General Electric Company: Key Strategic Moves and Developments
Table 96. GlaxoSmithKline plc: Key Executives
Table 97. GlaxoSmithKline plc: Company Snapshot
Table 98. GlaxoSmithKline plc: Operating Segments
Table 99. GlaxoSmithKline plc: Product Portfolio
Table 100. GlaxoSmithKline plc: Key Strategic Moves and Developments
Table 101. Medtronic plc: Key Executives
Table 102. Medtronic plc: Company Snapshot
Table 103. Medtronic plc: Operating Segments
Table 104. Medtronic plc: Product Portfolio
Table 105. Medtronic plc: Key Strategic Moves and Developments
Table 106. Merck and Co. Inc. : Key Executives
Table 107. Merck and Co. Inc. : Company Snapshot
Table 108. Merck and Co. Inc. : Operating Segments
Table 109. Merck and Co. Inc. : Product Portfolio
Table 110. Merck and Co. Inc. : Key Strategic Moves and Developments
Table 111. Siemens Ag: Key Executives
Table 112. Siemens Ag: Company Snapshot
Table 113. Siemens Ag: Operating Segments
Table 114. Siemens Ag: Product Portfolio
Table 115. Siemens Ag: Key Strategic Moves and Developments

List of Figures

Figure 1. Global Stroke Management Market Segmentation
Figure 2. Global Stroke Management Market
Figure 3. Segmentation Stroke Management Market
Figure 4. Top Investment Pocket in Stroke Management Market
Figure 5. Top Winning Strategies, 2019-2021*
Figure 6. Top Winning Strategies, by Development, 2019-2021(%)
Figure 7. Top Winning Strategies, by Company, 2019-2021*
Figure 8. Moderate Bargaining Power of Buyers
Figure 9. Moderate Bargaining Power of Suppliers
Figure 10. Moderate Threat of New Entrants
Figure 11. Low Threat of Substitution
Figure 12. High Competitive Rivalry
Figure 13. Top Player Positioning, 2020
Figure 14. Market Share Analysis, 2020
Figure 15. Restraints and Drivers: Stroke Management Market
Figure 16. Stroke Management Market Segmentation, by Type
Figure 17. Stroke Management Market for Diagnostics, by Country, 2020-2030 ($ Million)
Figure 18. Stroke Management Market for Therapeutics, by Country, 2020-2030 ($ Million)
Figure 19. Stroke Management Market Segmentation, by Application
Figure 20. Stroke Management Market for Ischemic Stroke, by Country, 2020-2030 ($ Million)
Figure 21. Stroke Management Market for Hemorrhagic Stroke, by Country, 2020-2030 ($ Million)
Figure 22. Abbott Laboratories: Net Sales, 2018-2020 ($ Million)
Figure 23. Abbott Laboratories: Revenue Share, by Segment, 2020 (%)
Figure 24. Abbott Laboratories: Revenue Share, by Region, 2020 (%)
Figure 25. B Braun Melsungen Ag: Net Sales, 2018-2020 ($ Million)
Figure 26. B Braun Melsungen Ag: Revenue Share, by Segment, 2020 (%)
Figure 27. B Braun Melsungen Ag: Revenue Share, by Region, 2020 (%)
Figure 28. Boston Scientific Corporation: Net Sales, 2018-2020 ($ Million)
Figure 29. Boston Scientific Corporation: Revenue Share, by Segment, 2020 (%)
Figure 30. Boston Scientific Corporation: Revenue Share, by Region, 2020 (%)
Figure 31. Bristol Myers Squibb Co: Net Sales, 2018-2020 ($ Million)
Figure 32. Bristol Myers Squibb Co: Revenue Share, by Segment, 2020 (%)
Figure 33. Bristol Myers Squibb Co: Revenue Share, by Region, 2020 (%)
Figure 34. Cardinal Health Inc: Net Sales, 2018-2020 ($ Million)
Figure 35. Cardinal Health Inc: Revenue Share, by Segment, 2020 (%)
Figure 36. Cardinal Health Inc: Revenue Share, by Region, 2020 (%)
Figure 37. General Electric Company: Net Sales, 2018-2020 ($ Million)
Figure 38. General Electric Company: Revenue Share, by Segment, 2020 (%)
Figure 39. General Electric Company: Revenue Share, by Region, 2020 (%)
Figure 40. GlaxoSmithKline plc: Net Sales, 2018-2020 ($ Million)
Figure 41. GlaxoSmithKline plc: Revenue Share, by Segment, 2020 (%)
Figure 42. GlaxoSmithKline plc: Revenue Share, by Region, 2020 (%)
Figure 43. Medtronic plc: Net Sales, 2018-2020 ($ Million)
Figure 44. Medtronic plc: Revenue Share, by Segment, 2020 (%)
Figure 45. Medtronic plc: Revenue Share, by Region, 2020 (%)
Figure 46. Merck and Co. Inc: Net Sales, 2018-2020 ($ Million)
Figure 47. Merck and Co. Inc: Revenue Share, by Segment, 2020 (%)
Figure 48. Merck and Co. Inc: Revenue Share, by Region, 2020 (%)
Figure 49. Siemens Ag: Net Sales, 2018-2020 ($ Million)
Figure 50. Siemens Ag: Revenue Share, by Segment, 2020 (%)
Figure 51. Siemens Ag: Revenue Share, by Region, 2020 (%)

Executive Summary

According to a new report titled, “Stroke Management Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2021–2030, the global stroke management market size was valued at $31,702.20 million in 2020, and is projected to reach $67,771.95 million by 2030, registering a CAGR of 7.8% from 2021 to 2030.

Stroke is the condition wherein a clot is formed in the artery and the oxygen supply to the brain is cut off. This leads to deprivation of oxygen to the brain cells, eventually causing death of brain tissue. A thrombotic stroke occurs when a blood clot is formed in the arteries that supply blood to the brain, whereas an embolic stroke forms away from brain, mainly due to the blood clot or deposition of debris in the heart, which causes narrowing of the brain arteries.

The major factors that drive the growth of stroke management market are increase in geriatric population and rise in prevalence of diseases such as diabetes. Moreover, rise in incidence of chronic diseases & diabetes, tobacco consumption, and constant technological developments for stroke management contribute toward the growth of the market. However, stringent government regulations pertaining to new product approvals for stroke management and lack of skilled professions for the diagnosis & treatment of stroke are expected to restrain the market growth during the forecast period. Conversely, ongoing R&D activities in the field of stroke management offers the lucrative growth for the market.

Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans. Amidst the initial outbreak of COVID-19, the reduced hospitals admissions of the stroke patients were observed. It was due fear about the infection during a period of distancing and lockdown. Various regions reported the reduction in acute stroke admissions in the hospital indicating that many patients with moderate and severe stroke were also avoiding the hospital presentation. For instance, according to the data of the National Institute of Health, in the central and south Texas, the patient admission, treatment, and discharge volumes for acute stroke treatment have decreased significantly since COVID-19-related lockdown orders were issued.

The demand for the diagnostic devices of the stroke and the monitoring devices were reduced. The production plants of the devices were shut down during the lockdown. This lockdown created the financial crisis among the market players. This further led to the disturbances in import and export of the devices across the countries. Overall, the impact of COVID-19 on the stroke management market was recorded to be fairly negative. This was attributed to decrease in the demand for the diagnostic devices of the stroke disease. Moreover, the market players have reduced the investment in raw materials and resources owing to the decrease in number of hospital admission of the stroke patients.

The stroke management market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into diagnostics and therapeutics. The diagnostics segment is classified into computed tomography scan (CT scan), magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others. The therapeutics segment is classified into tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive. By application, it is classified into is chemic stroke and hemorrhagic stroke. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

On the basis of type, the global stroke management market is classified into diagnostics and therapeutics. Diagnostics segment was the major contributor to the global market in 2020, and is anticipated to remain dominant during the forecast period, due to technological advancements in the stroke management devices, increase in adoption of stroke management devices, rise in incidence rate of chronic diseases like diabetes, and increase in number of advanced and effective product launches.

By application, the global stroke management market is classified into ischemic stroke and hemorrhagic stroke. Ischemic stroke segment was the major contributor to the global market in 2020, and is anticipated to remain dominant during the forecast period, due to increase in healthcare awareness, rise in incidence of diabetes, surge in number of tobacco users, and growth in geriatric population.

North America accounted for major share of the global stroke management market share in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to increase in incidences of chronic diseases like diabetes, surge in demand for stroke management devices, availability of advanced healthcare facilities with trained medical professionals, rise in number of R&D activities along with large presence of key players, and surge in investment made by governments in the healthcare system. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period. Moreover, Japan and China are expected to grow at high CAGR in Asia-Pacific stroke management market majorly due to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced instruments, development of the R&D sector, rise in healthcare reforms, and technological advancements in the field of stroke management.

Key Findings Of The Study

On the basis of type, the diagnostics segment held majority share in the global market in 2020
On the basis of application, the ischemic stroke segment held largest stroke management market share in 2020, and is expected to remain dominant throughout the forecast period
Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 91% during the forecast period

Companies Mentioned

Abbott Laboratories
B Braun Melsungen AG
Boston Scientific Corporation
Bristol-Myers Squibb Company
Cardinal Health Inc.
General Electric Company
GlaxoSmithKline Plc
Medtronic Plc
Merck & Co., Inc.
Siemens AG

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic news articles and other related releases for market evaluation
Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

LOADING...